Prognostic factors associated with shorter TTBM among patients with HER2+ BC included younger age at BC diagnosis, HR- versus HR+ status [15, 23, 30, 31], no receipt of trastuzumab versus receipt of trastuzumab [18, 23, 31], and higher tumor grade versus lower grades [21, 23]. This evidence concerns the gene ERBB2 and breast cancer.